ELECTRONIC LETTER

Recurrent deletion of a region containing exon 24 of the *RB1* gene caused by non-homologous recombination between a LINE-1HS and MER21B element

P Albrecht, J Bode, K Buiting, A K Prashanth, D R Lohmann

J Med Genet 2004;41:e122 (<http://www.jmedgenet.com/cgi/content/full/41/12/e122>). doi: 10.1136/jmg.2004.021923

About 10% of the mutations that are known to cause human monogenic disease are deletions of more than 20 bp (gross deletions). To date, 2127 disease causing gross deletions have been listed in the Human Gene Mutation Database (www.hgmd.org).¹ For only few of these mutations, breakpoints have been determined at the sequence level because this information is often of little relevance in clinical diagnostics. Those gross deletions that have been analysed in greater detail most often show DNA sequences with direct or inverted similarity at 5' and 3' breakpoints. The presence of repeated sequences has suggested models that help to explain the formation of these mutations.²

Mutations in the *RB1* gene can cause retinoblastoma, a childhood tumour of the eye. We have searched for gross deletions in samples of constitutional and tumour DNA from patients with this tumour. Most of these samples had previously been screened for *RB1* gene point mutations but with negative results. Using quantitative multiplex polymerase chain reaction (PCR)³ we identified a spectrum of gross deletions that was heterogeneous with respect to extent and location. In three patients, we found deletions in a region that contains exon 24 of the *RB1* gene. Further analysis showed that the 5' and 3' deletion breakpoints of these three mutations are located close to each other in an L1HS and MER21B element, respectively.⁴ These two DNA elements belong to different classes of interspersed repetitive DNA. The regions surrounding the 5' and 3' breakpoints do not show any sequence similarity. However, they are localised at the borders of strong scaffold/matrix attachment elements that mark the position of recombinogenic DNA structures.

METHODS

Samples

DNA from peripheral blood and from fresh frozen retinoblastoma samples was extracted as described previously.⁵ We investigated constitutional DNA from 60 patients with bilateral or familial retinoblastoma and tumour DNA from 85 patients with isolated unilateral retinoblastoma. Most of these samples had previously been searched for point mutations by Single-strand conformation polymorphism, heteroduplex analysis, or denaturing high performance liquid chromatography.⁶⁻⁷ DNA from tumour samples had also been analysed for hypermethylation of the CpG island associated with the promoter of the *RB1* gene⁸ and for loss of constitutional heterozygosity (LOH) at STR loci RB12 and RB1.20.

Quantitative multiplex PCR

Quantitative multiplex PCR was performed using the multiplex PCR assay described by Richter *et al*³ with only a few minor adaptations of primer sequences and controls. Products were analysed on an ABI 3100 Genetic Analyzer

Key points

- Retinoblastoma, a malignant tumour of the eye, is caused by mutations in the *RB1* gene. About 15–20% of oncogenic mutations in this gene are gross deletions.
- We have identified a recurrent deletion of a region containing exon 24 of the *RB1* gene in peripheral blood of three patients with retinoblastoma. The 5' and 3' deletion breakpoints of these deletions are clustered in an L1HS and MER21B element, respectively.
- The region of the deletion breakpoints does not show DNA sequences with direct or inverted similarity. However, the breakpoints are localised at the borders of strong scaffold/matrix attachment elements that mark the position of recombinogenic DNA structures.
- Our findings emphasise the role of scaffold/matrix attachment regions for deletion formation in humans.

(Applera). Peak integrals were determined using GeneScan and Genotyper software (Applera).

Long range PCR and sequencing

Long range PCR of a fragment spanning intron 23 to intron 26 of the *RB1* gene was performed as described by Bremner *et al*.⁹ To obtain smaller fragments spanning the deleted region, two long range PCRs were performed with primers GCT GGT TCA ATA TAC CA AAT CAA TA ATG (RBg166248se), TCA TCT GAT CCT TCA ATA TCA AAG CGT AGT (RBg173837as), and AAA AAT ATA AGC TCT CAG GGG AAT GGA GAT (RBg171908as) (fig 1). To detect both normal and mutant alleles in heterozygous samples, an additional long range PCR was performed using three primers in one reaction: RBg166248se, RBg171908as, and AGT TCA GAA TGA TGT ATT TAT GCT CAT CTC TGC (RBg170286se) (fig 2). RBg170286se binds to a sequence that is deleted in all three mutant alleles investigated here (fig 3A). PCRs with these three primers on samples heterozygous for one of the exon 24 deletions identified result in a product specific for the deleted allele and in a 1.6 kb product from the normal allele. For long range PCRs we used the Roche Expand Long Template kit (Roche, Mannheim, Germany).

For sequencing, the PCR products obtained with primers RBg166248se and RBg171908as were separated on a 1% agarose gel, cut out, and eluted. As sequencing primers we

Abbreviations: LINE, long interspersed nuclear elements; LOH, loss of constitutional heterozygosity; PCR, polymerase chain reaction; SIDD, stress induced duplex destabilisation; S/MARs, scaffold/matrix attachment regions

Figure 1 Long range PCR with primers RBg166248se and RBg171908as (for primer localisation also see fig 3A). PCR from DNA from a normal control shows the expected 5.7 kb product only. All three patients (blood DNA from M4716, and tumour DNA from M14400 and M3625) also show smaller junction products (labelled with asterisks) from *RB1* alleles with deletion mutations.

used RBg166248se, RBg171908as, AGG ACA CAA ACA AAT GGA AG (RBg166914se), and AAT TTA GGA TGG AAG CTG GT (RBg171317as). The products of sequencing reactions were analysed on an ABI 3100 Genetic Analyzer. The results of sequence analysis were compared using Lasergene sequence analysis software (DNASTAR, Madison WI, USA).

RESULTS AND DISCUSSION

Gross deletions were identified in 41 patients with retinoblastoma. In line with the results reported by Richter *et al*³ and Houdayer *et al*,¹⁰ the spectrum of gross deletions was heterogeneous with respect to extent and localisation. In both our data set and the data sets published by Richter *et al* and Houdayer *et al*, recurrent deletions that affect only a single exon are infrequent. Richter *et al* identified two mutations of this kind: a deletion of exon 17 in three patients and of exon 13 in two patients; Houdayer *et al* identified deletions of exon 2 and 8 in one patient each and a deletion of exon 3 in two patients. The breakpoint sequences of these deletions were not reported in the study of either group. In our series, three samples (peripheral blood DNA from patient M4716, tumour DNA from patient M14400, and tumour DNA from patient M3625) showed a deletion of exon 24 in quantitative multiplex PCR. All three samples had been screened for point mutations. The tumour samples from patient M14400 and from patient M3625, which showed no LOH at intragenic STR loci, were found to be heterozygous for a g.162237C→T (R787X) and a g.76999A→G (IVS15-2A→G) transition, respectively. To confirm and further characterise the gross deletions identified in the three samples, we performed long range PCR. Agarose gel electrophoresis of products spanning intron 23 to intron 26 and intron 23 to intron 24 showed smaller than expected DNA bands in all three samples (fig 1). Because of preferential amplification of the smaller products from mutant alleles, there was poor amplification of the products specific for the normal allele. We designed a three-primer PCR to obtain a more balanced product ratio in a single PCR assay. The result of the three-primer PCR indicated that, in constitutional DNA, all three patients are heterozygous for the mutant allele (fig 2). In patient M3625 this finding was unexpected because he had isolated unilateral retinoblastoma and less than 15% of these patients are carriers of *RB1* gene mutations.^{3,7} All three deletions occurred de novo because analysis of peripheral blood DNA from parents showed only normal *RB1* alleles. On

the level of the transcript the most probable consequence of all three gross deletions is loss of the 31 bp that correspond to exon 24, which results in a shift of the reading frame with premature termination eight triplets downstream. Splice donor site mutations in intron 24 that result in skipping of exon 24 lead to identical mutant transcripts. Mutations that involve this site have been reported in patients with bilateral and familial retinoblastoma.¹¹ Therefore, the gross deletions involving exon 24 identified here most likely cause predisposition to retinoblastoma in these patients. We further analysed the products of long range PCR by direct sequencing. Sequencing results were compared to the published sequence of the *RB1* gene (GenBank accession number L11910) and to the results of sequence analysis of a sample without deletion. Patient M14400 showed a deletion of 3605 bp (fig 3). The 5' breakpoint is located in intron 23 at nucleotide 167157 (RBg167157) in a region of 6017 bp with high sequence similarity to an LIHS, a member of the family of long interspersed nuclear elements (LINE).¹² The 3' breakpoint of the mutation is located in intron 24 at RBg170762 within a 764 bp region with similarity to the DNA transposon MER21B. Interestingly, the 5' and 3' breakpoints of the deletions identified in the other two patients are located in the same interspersed repetitive DNA elements. In patient M4716, the 5' and 3' breakpoints are located after nucleotide position RBg167672 and RBg171215, respectively. In addition to loss of bases RBg167673 to 171214, the mutant allele also shows an insertion of 19 bp. A BLASTn sequence comparison of this inserted sequence to the human genome showed no significant similarities to any sequence mapped on chromosome 13. The deletion identified in the sample of patient M3625 is more complex. The mutant allele may be described as a combination of a 2988 bp deletion (del167988^170975) and an insertion of 3 bp (ins167988insACT). However, this interpretation cannot account for four mismatches located 95 bp (RBg167893), 68 bp (RBg167920), 51 bp (RBg16737), and 1 bp (RBg167988) upstream of the most distal possible 5' breakpoint location. A BLASTn similarity search against the human genome showed that the 95 bp sequence ranging from the first mismatch (RBg167893) to the 5' breakpoint (RBg167988) is identical only to one sequence (in the opposite direction) that is located in intron 17 of the *RB1* gene (RBg79218 to RBg 79123) (fig 3). This region in intron 17 is situated in a 1.3 kb long L1PA5 element (RBg78540 to RBg79873), a truncated member of the LINE family.

Recurrent loss of only a single exon of the *RB1* gene is rare. Intriguingly, there is a clustering of the locations of 3' and 5' deletion breakpoints of the exon 24 deletions identified here. The 5' breakpoints have a maximum distance of 830 bp and are located in an LIHS LINE. This LIHS has 97% similarity to the full length retrotransposition competent L1 (L1.3, GenBank accession no. L19092) but has acquired

Figure 2 Three-primer PCR with the same primers as in fig 1 plus RBg170286se (see also fig 3A). The presence of the wild type allele is indicated by a PCR product of 1.6 kb. PCR products from *RB1* alleles with deletion mutations (labelled with asterisks) are only detected in the patients (blood DNA from M4716, M14400, and M3625). Due to preferential amplification of the shorter fragments, the 5.7 kb fragment is not detected on the gel.

Figure 3 (A) Genomic organisation of a part of the *RB1* gene and location of repetitive elements L1PA5, L1HS, and MER21B. The locations of exon 17 and exons 21 to 25 are indicated by vertical grey bars. Sequence similarity between L1HS and L1PA5 is indicated by light and dark blue colour. The 95 bp region identical to the sequence at the 5' breakpoint of patient M3625 is indicated by a vertical red bar in intron 17. (B) Nucleotide sequence alignment of the deletion mutants (A[^]D) and the normal allele. Normal sequences from the 5' breakpoints (A[^]B) within the L1HS are displayed in blue, normal sequences from the 3' breakpoints (C[^]D) within the MER21B in green, and the sequence from intron 17 in red.

Figure 4 MAR potential of the BCR regions (indicated by the black bars) according to two algorithms, Mar-Finder (A) and SIDD (B). A S/MAR is a base-unpairing region that is characterised by a succession of destabilised sites, the so called unpairing elements. The flanks of a S/MAR give rise to DNA transition structures which in turn are the preferred targets of retroelement integration, deletion, and translocation events as described in the text. Such events occur neither in the centre of a S/MAR nor in extended S/MAR free regions.^{16–19}

several sequence changes that truncate the two open reading frames that are part of a functional L1. ORF1 and ORF2 of an L1 element encode an RNA binding protein and a protein with endonuclease and reverse transcriptase activities, respectively. Both proteins are necessary for the retrotransposition activity of these autonomous transposable elements.⁴ As sequence changes have destroyed the coding potential of the L1HS in intron 23 of the *RB1* gene, this element is most likely not an active LINE. Therefore, a deletional mechanism involving active retrotransposition of this transposon is unlikely. The 3' breakpoints of the three deletions have a maximum distance of only 235 bp and are located in a MER21B DNA transposon fossil.¹³ L1HS and MER21B belong to different classes of interspersed repetitive DNA and show no significant sequence similarity. A search for direct and reverted repeats as well as symmetric elements (using DNASTAR software) identified no significant sequence similarity between 5' and 3' breakpoint regions. Therefore, the most common pattern for the occurrence of deletions including the formation of deletion facilitating secondary structures due to sequence similarities between proximal and distal breakpoint areas, as described by Chuzhanova *et al.*,² is not a likely explanation for the deletions observed in this work.

In the mammalian nucleus the genome is subdivided into about 60 000 chromatin loops by periodic attachments to a nuclear substructure called the nuclear matrix or nuclear scaffold.^{14–19} These attachment points are provided by S/MARs (scaffold/matrix attachment regions), that is, sequences of a minimum length of 300 bp without an apparent sequence consensus.^{15–17} Although prototype elements are AT rich, a distinct distribution of AT rich tracts rather than overall base composition determines their activity.¹⁸ This pattern mediates a propensity for local strand unpairing^{14–15} which is, at least in part, utilised in the living cell. Owing to this base-unpairing potential, S/MARs have been considered as recombinogenic structures¹⁶ and therefore as the preferred sites for integrating retroelements.²⁰ Retroelements have consequently been interpreted as markers for the presence of a S/MAR.¹⁶

While these facts have been elaborated some time ago, more thorough recent analyses have shown that sites of genomic fragility mainly arise at the edges of a S/MAR, that is, at transition structures between B-type and ss-DNA which are frequently characterised by increased accessibility for DNase.^{16–19} The matrix binding sequence itself is largely protected from recombination events, probably because they are associated with proteins of ss-DNA recognition potential. Our present study suggests that also in case of the *RB1* gene S/MARs flanking regions are the preferred sites triggering deletion events.

During recent years, several software tools have been developed for the prediction of S/MARs. An early example, the “MAR-finder”²¹ (now known as MARwiz, <http://www.futuresoft.org/MarFinder/>) is based on the statistical occurrence of S/MAR motifs typical for replication origins, TG rich motifs, curved/kinked DNA, topoisomerase II consensus, and AT rich sequences. The “stress induced duplex destabilisation” (SIDD) approach identifies regions of DNA unwinding associated with nuclear matrix binding using a statistical mechanical procedure.^{15–20} There are many cases where the prediction of these two approaches is in close agreement.²⁰ Figure 4 shows a superimposition of both analysis schemes. Here the MAR-finder positions the two breakpoint cluster region (BCR) genes in locations of minimum MAR potential (0.1–0.3). In the case of the SIDD profile, the centre (approximate map positions 1100–3500) is marked by a regular succession of destabilised sites which are analysed at a standard superhelical density of $\sigma = -0.055$. This architecture is typical of strong S/MAR elements as it allows the mass binding mode for prototypical matrix proteins such as the lamins and scaffold attachment factor A.^{17–18} On both sides of this base-unpairing region there are segments of DNA that are stabilised at about 8–10 kcal/mol and, based on the combined evidence of both analysis schemes, do not have a S/MAR character. It is clearly seen that these S/MAR associated regions are the primary locations of the deletion endpoints thus confirming the concept that emerged from previous studies.

In conclusion, we have identified two deletion breakpoint clusters in the *RB1* gene that are involved in recurrent gross deletions in patients with retinoblastoma. The putative mechanism underlying these mutations highlights the importance of S/MARs for deletion formation in humans.

ELECTRONIC-DATABASE INFORMATION

The URL of the Human Gene Mutation Database is www.hgmd.org and that of the MAR-finder is <http://www.futuresoft.org/MarFinder/>.

Authors' affiliations

P Albrecht, K Buiting, D R Lohmann, Institut für Humangenetik, Universitätsklinikum Essen, Essen, Germany
J Bode, GBF, German Research Center for Biotechnology/Epigenetic Regulation, D-38124 Braunschweig, Germany
A K Prashanth, UC Davis Genome Center Davis, Davis, CA 95616-8816, USA

This study was supported by the Deutsche Forschungsgemeinschaft (Klinische Forschergruppe Ophthalmologische Onkologie und Genetik, DFG KFO 109/1-1, TP II-1).

Conflict of interest: none declared.

Ethics approval: Diagnostic mutation analysis was performed conforming to national guidelines. Scientific analysis of the data was approved by the ethics committee of the Medizinische Fakultät der Universität Essen (file # 01-100-1700).

Correspondence to: Dietmar Lohmann, Institut für Humangenetik, Universitätsklinikum Essen, Hufelandstrasse 55, IG1, 45122 Essen, Germany; retinoblastoma@genetik-nrw.de

Revised version received 30 June 2004

Accepted for publication 2 July 2004

REFERENCES

- 1 Stenson PD, Ball EV, Mort M, Phillips AD, Shiel JA, Thomas NS, Abeyasinghe S, Krawczak M, Cooper DN. Human Gene Mutation Database (HGMD): 2003 update. *Hum Mutat* 2003;**21**(6):577–81.
- 2 Chuzhanova N, Abeyasinghe SS, Krawczak M, Cooper DN. Translocation and gross deletion breakpoints in human inherited disease and cancer II: potential involvement of repetitive sequence elements in secondary structure formation between DNA ends. *Hum Mutat* 2003;**22**(3):245–51.
- 3 Richter S, Vandezande K, Chen N, Zhang K, Sutherland J, Anderson J, Han L, Pantan R, Branco P, Gallie B. Sensitive and efficient detection of RB1 gene mutations enhances care for families with retinoblastoma. *Am J Hum Genet* 2003;**72**(2):253–69.
- 4 Ostertag EM, Kazazian HH Jr. Biology of mammalian L1 retrotransposons. *Annu Rev Genet* 2001;**35**:501–38.
- 5 Kunkel LM, Smith KD, Boyer SH, Borgaonkar DS, Watchel SS, Miller OJ, Breg WR, Jones HW Jr, Ray JM. Analysis of human Y-chromosome specific reiterated DNA in chromosome variants. *Proc Natl Acad Sci U S A* 1977;**74**(3):1245–9.
- 6 Lohmann DR, Brandt B, Hopping W, Passarge E, Horsthemke B. The spectrum of RB1 germ-line mutations in hereditary retinoblastoma. *Am J Hum Genet* 1996;**58**(5):940–9.
- 7 Lohmann DR, Gerick M, Brandt B, Oelschlager U, Lorenz B, Passarge E, Horsthemke B. Constitutional RB1-gene mutations in patients with isolated unilateral retinoblastoma. *Am J Hum Genet* 1997;**61**(2):282–94.
- 8 Zeschnick M, Lohmann D, Horsthemke B. A PCR test for the detection of hypermethylated alleles at the retinoblastoma locus. *J Med Genet* 1999;**36**(10):793–4.
- 9 Bremner R, Du DC, Connolly-Wilson MJ, Bridge P, Ahmad KF, Mostachfi H, Rushlow D, Dunn JM, Gallie BL. Deletion of RB exons 24 and 25 causes low-penetrance retinoblastoma. *Am J Hum Genet* 1997;**61**(3):556–70.
- 10 Houdayer C, Gauthier-Villars M, Lauge A, Pages-Berhouet S, Dehainault C, Caux-Moncoutier V, Karczynski P, Tosi M, Doz F, Desjardins L, Couturier J, Stoppa-Lyonnet D. Comprehensive screening for constitutional RB1 mutations by DHPLC and QMPSF. *Hum Mutat* 2004;**23**(2):193–202.
- 11 Lohmann DR. RB1 gene mutations in retinoblastoma. *Hum Mutat* 1999;**14**(4):283–8.
- 12 Toguchida J, McGee TL, Paterson JC, Eagle JR, Tucker S, Yandell DW, Dryja TP. Complete genomic sequence of the human retinoblastoma susceptibility gene. *Genomics* 1993;**17**(3):535–43.
- 13 The International Human Genome Sequencing Consortium. Initial sequencing and analysis of the human genome. *Nature* 2001;**409**(6822):860–921.
- 14 Bode J, Kohwi Y, Dickinson L, Joh T, Klehr D, Mielke C, Kohwi-Shigematsu T. Biological significance of unwinding capability of nuclear matrix-associating DNAs. *Science* 1992;**255**(5041):195–7.
- 15 Benham C, Kohwi-Shigematsu T, Bode J. Stress-induced duplex DNA destabilization in scaffold/matrix attachment regions. *J Mol Biol* 1997;**274**(2):181–96.
- 16 Bode J, Benham C, Ernst E, Knopp A, Marschalek R, Strick R, Strissel P. Fatal connections: when DNA ends meet on the nuclear matrix. *J Cell Biochem Suppl* 2000;**35**:3–22.
- 17 Bode J, Benham C, Knopp A, Mielke C. Transcriptional augmentation: modulation of gene expression by scaffold/matrix-attached regions (S/MAR elements). *Crit Rev Eukaryot Gene Expr* 2000;**10**(1):73–90.
- 18 Bode J, Goetze S, Heng H, Krawetz SA, Benham C. From DNA structure to gene expression: mediators of nuclear compartmentalization and dynamics. *Chromosome Res* 2003;**11**(5):435–45.
- 19 Hensel JP, Gillert E, Fey GH, Marschalek R. Breakpoints of t(4;11) translocations in the human MLL and AF4 genes in ALL patients are preferentially clustered outside of high-affinity matrix attachment regions. *J Cell Biochem* 2001;**82**(2):299–309.
- 20 Goetze S, Huesemann Y, Baer A, Bode J. Functional characterization of transgene integration patterns by halo fluorescence in situ hybridization: electroporation versus retroviral infection. *Biochemistry* 2003;**42**(23):7035–43.
- 21 Singh GB, Kramer JA, Krawetz SA. Mathematical model to predict regions of chromatin attachment to the nuclear matrix. *Nucleic Acids Res* 1997;**25**(7):1419–25.